Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 747-759 , December 2007

Role of autologous stem-cell transplantation in multiple myeloma

  • Michel Attal, MD (Professor of Hematology and Head of Hematology Department)
  • Jean-Luc Harousseau, MD (Professor of Hematology and Head of Hematology Department)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +33 2 40 08 32 71; Fax: +33 2 40 08 32 50.

References 

  1. Barlogie B, Hall R, Zander A, et al. High-dose Melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67:1298–1301
  2. Barlogie B, Alexanian R, Dicke KA, et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70:869–872
  3. Attal M, Harousseau JL, Stoppa AM, et al. for the Intergroupe Français du Myélome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. The New England Journal of Medicine. 1996;335:91–97
  4. Child JA, Morgan GJ, Davies FE, et al. Medical research Council Adult Leukemia Working Party: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. The New England Journal of Medicine. 2003;348:1875–1883
  5. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma:up-front or rescue treatment? Results of a multicenter sequential randomized trial. Blood. 1998;92:3131–3136
  6. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Groupe Myelome-Autogreffe. Journal of Clinical Oncology. 2005;23:9227–9233
  7. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology. 1998;102:1115–1123
  8. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473
  9. Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative groupe PETHEMA. Blood. 2005;106:3755–3759
  10. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. Journal of Clinical Oncology. 2006;24:929–936
  11. Alexanian R, Dimopoulos MA, Hester J, et al. Early myeloablative therapy for multiple myeloma. Blood. 1994;84:4278–4282
  12. Kumar S, Lacy MQ, Dispenzieri A, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplantation. 2004;34:161–167
  13. Harousseau JL, Milpied N, Laporte JP, et al. Double-intensive therapy in high-risk multiple myeloma. Blood. 1992;79:3131–3136
  14. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55–65
  15. Attal M, Harousseau JL, Facon T, et al. Intergroupe Francophone du Myélome:single versus double autologous stem cell transplantation for multiple myeloma. The New England Journal of Medicine. 2003;349:2495–2502
  16. Cavo M, Tosi P, Zamagni E, et al. Prospective randomized study of single compared with double autologous stem cell transplantation for Multiple Myeloma: Bologna 96 clinical study. Journal of Clinical Oncology. 2007;25:2434–2441
  17. Sonneveld P, Van Der Holt B, Segeren CM, et al. Intermediate-dose Melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Deutch Cooperative Group HOVON 24 trial. Haematologica. 2007;92:928–935
  18. Barlogie B, Tricot G, Rabmussen E, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and post-transplantation consolidation therapies. Blood. 2006;107:2633–2638
  19. Moreau P, Hullin C, Garban F, et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood. 2006;107:397–403
  20. Rajkumar V, Blaad E, Vesole D, et al. Phase III clinical trial of Thalidomide plus Dexamethasone compared with Dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology. 2006;24:431–436
  21. Cavo M, Zamagni E, Tosi P, et al. Superiority of Thalidomide and Dexamethasone over Vincristine-Doxorubicine-Dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35–39
  22. Goldschmidt H, Sonneveld P, Breitkreuz I, et al. HOVON 50/GMMG-HD3 trial: Phase III study on the effect of Thalidomide combined with high-dose Melphalan in myeloma patients up to 65 years. Blood. 2005;106:128a;(abstract)
  23. Macro M, Divine M, Uzunban Y, et al. Dexamethasone + Thalidomide compared to VAD as pre-transplant treatment in newly diagnosed multiple myeloma: a randomized trial. Blood. 2006;108:22a;(abstract)
  24. Jagannath S, Durie B, Wolf J, et al. Bortezomib therapy alone and in combination with Dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology. 2005;129:776–783
  25. Oakervee HE, Pollat R, Curry N, et al. PAD combination therapy (PS341, Doxorubicin and Dexamethasone) for untreated multiple myeloma. British Journal of Haematology. 2005;755–762
  26. Popat R, Oakervee HE, Curry N, et al. Reduced dose PAD (PS 341, Adriamycin and Dexamethasone) for previously untreated patients with multiple myeloma. Blood. 2005;106:717a;(abstract)
  27. Harousseau JL, Attal M. Bortezomib plus Dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Haematologica. 2006;91:1498–1505
  28. Barlogie B, Tricot G, Rasmussen E, et al. Total therapy incorporating Velcade into upfront management of multiple myeloma: comparison with TT2 + Thalidomide. Blood. 2005;106:337a;(abstract)
  29. Wang M, Delaballe K, Giralt S, et al. Rapid control of previously untreated multiple myeloma with Bortezomib-Thalidomide-Dexamethasone followed by early intensive therapy. Blood. 2005;106:231a;(abstract)
  30. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone for newly diagnosed myeloma. Blood. 2005;106:4050–4053
  31. Attal M, Harousseau JL, Leyvras S, et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood. 2006;15:3289–3294
  32. Spencer A, Prince M, Roberts AW, et al. First analysis of the Australian leukaemia and lymphoma group trial of Thalidomide and alternate day Prednisone following autologous stem cell transplantation for patients with multiple myeloma. Blood. 2006;108:22a;(abstract)
  33. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic cell transplantation for multiple myeloma. The New England Journal of Medicine. 2006;354:1021–1030
  34. Siegel DS, Desikan KR, Nehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93:51–54
  35. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. British Journal of Haematology. 2001;114:600–607
  36. Palumbo A, Triolo S, Argentin C. Dose intensive melphalan with stem-cell support is superior to standard treatment in elderly myeloma patients. Blood. 1999;94:1248–1253
  37. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose Melphalan improves survival of myeloma patients aged 50-70: results of a randomized controlled trial. Blood. 2004;3052–3057
  38. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007 Oct 6;370(9594):1209–1218
  39. Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. British Journal of Haematology. 2001;114:822–829
  40. Tosi P, Zamagni E, Ronconi S, et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and renal failure. Leukemia. 2000;14:1310–1313
  41. San Miguel J, Lahuerta JJ, Garcia-Sanz R, et al. Are myeloma patients with renal failure candidate for autologous stem cell transplantation. The Hematology Journal. 2000;1:28–36
  42. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:66–75
  43. Vesole D, Tricot G, Jagannath S, et al. Autotransplant in multiple myeloma: What have we learned?. Blood. 1996;88:838–847
  44. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by Fish analysis and serum b2 microglobulin produce powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566–1571
  45. Tricot G, Spencer T, Sawyer J, et al. Predicting long-term (≥ 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplant. British Journal of Haematology. 2002;116:211–217
  46. Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003;101:3849–3856
  47. Fassas AT, Spencer T, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. British Journal of Haematology. 2002;118:1041–1047
  48. Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. British Journal of Haematology. 2004;125:64–68
  49. Gertz M, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14) (q13;q32), t(4;14) (p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005;106:2837–2840
  50. Jaksic W, Trudel S, Chang H, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. Journal of Clinical Oncology. 2005;23:7069–7073
  51. Chang H, Qi C, Yi QL, et al. p53 gene deletion detected by fluorescence in situ hybridisation is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005;105:358–360
  52. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007;109:3489–3495
  53. Palumbo A, Bringhen S, Caravita T, et al. Oral Melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825–831
  54. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006 Oct 1;108(7):2165–2172[Epub 2006 Jun 13]
  55. Palumbo A, Falco P, Falcone A, et al. Oral Revlimid plus Melphalan and Prednisone for newly diagnosed multiple myeloma: results of a multicenter phase I/II study. Blood. 2006;online
  56. Lacy M, Gertz M, Dispenzieri A, et al. Lenalidomide plus Dexamethasone in Newly diagnosed myeloma: response to therapy, time to progression and survival. Blood. 2006;108:230a;(abstract)

PII: S1521-6926(07)00072-2

doi: 10.1016/j.beha.2007.09.006

Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 747-759 , December 2007

Article Tools